Zoi Capital Managing Director, Dr. Ron Razmi, joined Tyler Mathison and Kelly Evans, to discuss the potential of health AI as an attractive sector for investments in public and private markets. The discussion covered a range of related issues including regulation of health AI by the FDA, the role of AI in drug discovery, short-term applications in healthcare administration and operations, and how soon the public investors can expect to see promising health AI companies on major exchanges
From the interview: “AI in drug discovery is an area where investors have lost money because they underestimated how long it will take to find new drugs using AI and bring them to the market”
